-
1
-
-
0036169418
-
Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001
-
Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol 2002;20(1):3-9.
-
(2002)
Semin Urol Oncol
, vol.20
, Issue.1
, pp. 3-9
-
-
Sarma, A.V.1
Schottenfeld, D.2
-
2
-
-
0036256059
-
Prostate cancer update
-
Rini BI, Small EJ. Prostate cancer update. Curr Opin Oncol 2002;14(3):286-291.
-
(2002)
Curr Opin Oncol
, vol.14
, Issue.3
, pp. 286-291
-
-
Rini, B.I.1
Small, E.J.2
-
3
-
-
0032323546
-
Management of hormone refractory prostate cancer: Current standards and future prospects
-
Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: Current standards and future prospects [see comments]. J Urol 1998;160(4):1220-1229.
-
(1998)
J Urol
, vol.160
, Issue.4
, pp. 1220-1229
-
-
Oh, W.K.1
Kantoff, P.W.2
-
4
-
-
0036671675
-
Chemotherapy for androgen-independent prostate cancer
-
Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002;20(3 Suppl 1):31-35.
-
(2002)
Semin Urol Oncol
, vol.20
, Issue.3 SUPPL. 1
, pp. 31-35
-
-
Petrylak, D.P.1
-
5
-
-
0034862531
-
Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven
-
Woynarowska BAL, Munoz RM, Bushong P, Waters SJ. Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven. Invest New Drugs 2001;19(4):283-291.
-
(2001)
Invest New Drugs
, vol.19
, Issue.4
, pp. 283-291
-
-
Woynarowska, B.A.L.1
Munoz, R.M.2
Bushong, P.3
Waters, S.J.4
-
6
-
-
0034657646
-
Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF)
-
Woynarowska BA, Woynarowski JM, Herzig MC, Roberts K, Higdon AL, MacDonald JR. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 2000;59(10):1217-1226.
-
(2000)
Biochem Pharmacol
, vol.59
, Issue.10
, pp. 1217-1226
-
-
Woynarowska, B.A.1
Woynarowski, J.M.2
Herzig, M.C.3
Roberts, K.4
Higdon, A.L.5
MacDonald, J.R.6
-
7
-
-
0033819653
-
Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells
-
Woynarowska BA, Roberts K, Woynarowski JM, MacDonald JR, Herman TS. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res 2000;154(4):429-438.
-
(2000)
Radiat Res
, vol.154
, Issue.4
, pp. 429-438
-
-
Woynarowska, B.A.1
Roberts, K.2
Woynarowski, J.M.3
MacDonald, J.R.4
Herman, T.S.5
-
8
-
-
0034778514
-
Preclinical pharmacology of BMS-275183, an orally active taxane
-
Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001;7(7):2016-2021.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.7
, pp. 2016-2021
-
-
Rose, W.C.1
Long, B.H.2
Fairchild, C.R.3
Lee, F.Y.4
Kadow, J.F.5
-
9
-
-
0034883764
-
Paclitaxel and docetaxel in prostate cancer
-
Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001;15(3):525-545.
-
(2001)
Hematol Oncol Clin North Am
, vol.15
, Issue.3
, pp. 525-545
-
-
Obasaju, C.1
Hudes, G.R.2
-
10
-
-
0033457887
-
A phase II study of docetaxel (taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B Trial 9780
-
Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. A phase II study of docetaxel (taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol 1999;26(5 Suppl 17):39-44.
-
(1999)
Semin Oncol
, vol.26
, Issue.5 SUPPL. 17
, pp. 39-44
-
-
Savarese, D.1
Taplin, M.E.2
Halabi, S.3
Hars, V.4
Kreis, W.5
Vogelzang, N.6
-
11
-
-
0035340275
-
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780
-
Cancer and Leukemia Group B
-
Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang N. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19(9):2509-2516.
-
(2001)
J Clin Oncol
, vol.19
, Issue.9
, pp. 2509-2516
-
-
Savarese, D.M.1
Halabi, S.2
Hars, V.3
Akerley, W.L.4
Taplin, M.E.5
Godley, P.A.6
Hussain, A.7
Small, E.J.8
Vogelzang, N.9
-
12
-
-
0035886470
-
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma
-
DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, et al. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer 2001;92(8):2065-2071.
-
(2001)
Cancer
, vol.92
, Issue.8
, pp. 2065-2071
-
-
DiPaola, R.S.1
Chenven, E.S.2
Shih, W.J.3
Lin, Y.4
Amenta, P.5
Goodin, S.6
-
13
-
-
0033452117
-
Approaches to the treatment of patients with hormone-sensitive prostate cancer
-
DiPaola RS. Approaches to the treatment of patients with hormone-sensitive prostate cancer. Semin Oncol 1999;26(5 Suppl 17):24-27.
-
(1999)
Semin Oncol
, vol.26
, Issue.5 SUPPL. 17
, pp. 24-27
-
-
DiPaola, R.S.1
-
14
-
-
0028826389
-
RTOG's first quality of life study - RTOG 90-20: A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer
-
Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, et al. RTOG's first quality of life study - RTOG 90-20: A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 1995;33(4):901-906.
-
(1995)
Int J Radiat Oncol Biol Phys
, vol.33
, Issue.4
, pp. 901-906
-
-
Watkins-Bruner, D.1
Scott, C.2
Lawton, C.3
DelRowe, J.4
Rotman, M.5
Buswell, L.6
-
15
-
-
0028237218
-
Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer
-
Beard C, Buswell L, Rose MA, Noll L, Johnson D, Coleman CN. Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 1994;29(3):611-616.
-
(1994)
Int J Radiat Oncol Biol Phys
, vol.29
, Issue.3
, pp. 611-616
-
-
Beard, C.1
Buswell, L.2
Rose, M.A.3
Noll, L.4
Johnson, D.5
Coleman, C.N.6
-
16
-
-
0036284485
-
Metabolic radiotherapy: What role will it have in 2001?
-
George B, Douard MC, Rain JD. [Metabolic radiotherapy: What role will it have in 2001?]. Cancer Radiother 2002;6(3):188-200.
-
(2002)
Cancer Radiother
, vol.6
, Issue.3
, pp. 188-200
-
-
George, B.1
Douard, M.C.2
Rain, J.D.3
-
17
-
-
0030867207
-
Cancer chemoprevention and therapy by monoterpenes
-
Gould MN. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 1997;105(Suppl 4):977-979.
-
(1997)
Environ Health Perspect
, vol.105
, Issue.SUPPL. 4
, pp. 977-979
-
-
Gould, M.N.1
-
18
-
-
0029841196
-
Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer
-
Crowell PL, Siar Ayoubi A, Burke YD. Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Adv Exp Med Biol 1996;401:131-136.
-
(1996)
Adv Exp Med Biol
, vol.401
, pp. 131-136
-
-
Crowell, P.L.1
Siar Ayoubi, A.2
Burke, Y.D.3
-
19
-
-
0032980875
-
Prevention and therapy of cancer by dietary monoterpenes
-
Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999;129(3):775S-778S.
-
(1999)
J Nutr
, vol.129
, Issue.3
-
-
Crowell, P.L.1
-
20
-
-
0032827382
-
Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines
-
Sahin MB, Perman SM, Jenkins G, Clark SS. Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia 1999;13(10):1581-1591.
-
(1999)
Leukemia
, vol.13
, Issue.10
, pp. 1581-1591
-
-
Sahin, M.B.1
Perman, S.M.2
Jenkins, G.3
Clark, S.S.4
-
21
-
-
0031427722
-
Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells
-
Stayrook KR, McKinzie JH, Burke YD, Burke YA, Crowell PL. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 1997;18(8):1655-1658.
-
(1997)
Carcinogenesis
, vol.18
, Issue.8
, pp. 1655-1658
-
-
Stayrook, K.R.1
McKinzie, J.H.2
Burke, Y.D.3
Burke, Y.A.4
Crowell, P.L.5
-
22
-
-
0029055687
-
The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol
-
Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MN. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 1995;91(2):169-175.
-
(1995)
Cancer Lett
, vol.91
, Issue.2
, pp. 169-175
-
-
Gelb, M.H.1
Tamanoi, F.2
Yokoyama, K.3
Ghomashchi, F.4
Esson, K.5
Gould, M.N.6
-
23
-
-
0029125753
-
Differential effects of monoterpenes and lovastatin on RAS processing
-
Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 1995;270(29):17508-17512.
-
(1995)
J Biol Chem
, vol.270
, Issue.29
, pp. 17508-17512
-
-
Hohl, R.J.1
Lewis, K.2
-
24
-
-
0033561642
-
Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol
-
Ariazi EA, Satomi Y, Ellis MJ, Haag JD, Shi W, Sattler CA, et al. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 1999;59(8):1917-1928.
-
(1999)
Cancer Res
, vol.59
, Issue.8
, pp. 1917-1928
-
-
Ariazi, E.A.1
Satomi, Y.2
Ellis, M.J.3
Haag, J.D.4
Shi, W.5
Sattler, C.A.6
-
25
-
-
0033976684
-
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day
-
Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, et al. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 2000;6(2):390-396.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.2
, pp. 390-396
-
-
Ripple, G.H.1
Gould, M.N.2
Arzoomanian, R.Z.3
Alberti, D.4
Feierabend, C.5
Simon, K.6
-
26
-
-
15644376846
-
Phase I clinical trial of perillyl alcohol administered daily
-
Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998;4(5):1159-1164.
-
(1998)
Clin Cancer Res
, vol.4
, Issue.5
, pp. 1159-1164
-
-
Ripple, G.H.1
Gould, M.N.2
Stewart, J.A.3
Tutsch, K.D.4
Arzoomanian, R.Z.5
Alberti, D.6
-
27
-
-
0033875499
-
Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies
-
Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, et al. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 2000;6(8):3071-3080.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.8
, pp. 3071-3080
-
-
Hudes, G.R.1
Szarka, C.E.2
Adams, A.3
Ranganathan, S.4
McCauley, R.A.5
Weiner, L.M.6
-
29
-
-
0032932315
-
Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells
-
Del Bino G, Darzynkiewicz Z, Degraef C, Mosselmans R, Fokan D, Galand P. Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells. Cell Prolif 1999;32(1):25-37.
-
(1999)
Cell Prolif
, vol.32
, Issue.1
, pp. 25-37
-
-
Del Bino, G.1
Darzynkiewicz, Z.2
Degraef, C.3
Mosselmans, R.4
Fokan, D.5
Galand, P.6
-
30
-
-
0030964237
-
Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis
-
Uslu R, Borsellino N, Frost P, Garban H, Ng CP, Mizutani Y, et al. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 1997;3(6):963-972.
-
(1997)
Clin Cancer Res
, vol.3
, Issue.6
, pp. 963-972
-
-
Uslu, R.1
Borsellino, N.2
Frost, P.3
Garban, H.4
Ng, C.P.5
Mizutani, Y.6
-
31
-
-
0032798761
-
Sensitization of immunoresistant prostate carcinoma cell lines to Fas/ Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis
-
Frost PJ, Belldegrun A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis. Prostate 1999;41(1):20-30.
-
(1999)
Prostate
, vol.41
, Issue.1
, pp. 20-30
-
-
Frost, P.J.1
Belldegrun, A.2
Bonavida, B.3
-
32
-
-
14444279883
-
Fas-mediated apoptosis in human prostatic carcinoma cell lines
-
Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57(9):1758-1768.
-
(1997)
Cancer Res
, vol.57
, Issue.9
, pp. 1758-1768
-
-
Rokhlin, O.W.1
Bishop, G.A.2
Hostager, B.S.3
Waldschmidt, T.J.4
Sidorenko, S.P.5
Pavloff, N.6
-
33
-
-
0031586323
-
Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity
-
Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 1997;180(1):70-83.
-
(1997)
Cell Immunol
, vol.180
, Issue.1
, pp. 70-83
-
-
Frost, P.1
Ng, C.P.2
Belldegrun, A.3
Bonavida, B.4
-
34
-
-
0037099557
-
Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
-
Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, et al. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer 2002;95(2):296-300.
-
(2002)
Cancer
, vol.95
, Issue.2
, pp. 296-300
-
-
Jiang, J.1
Ulbright, T.M.2
Zhang, S.3
Eckert, G.J.4
Kao, C.5
Gardner, T.A.6
-
35
-
-
0031838286
-
Immunohistochemical study of Fas, Fas ligand, and interleukin-1 beta converting enzyme expression in human prostatic cancer
-
Sasaki Y, Ahmed H, Takeuchi T, Moriyama N, Kawabe K. Immunohistochemical study of Fas, Fas ligand, and interleukin-1 beta converting enzyme expression in human prostatic cancer. Br J Urol 1998;81(6):852-855.
-
(1998)
Br J Urol
, vol.81
, Issue.6
, pp. 852-855
-
-
Sasaki, Y.1
Ahmed, H.2
Takeuchi, T.3
Moriyama, N.4
Kawabe, K.5
-
36
-
-
0031834910
-
Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
-
Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage. Prostate 1998;36(2):92-101.
-
(1998)
Prostate
, vol.36
, Issue.2
, pp. 92-101
-
-
Hedlund, T.E.1
Duke, R.C.2
Schleicher, M.S.3
Miller, G.J.4
-
37
-
-
0033057792
-
Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
-
Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, et al. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 1999;6(2):175-182.
-
(1999)
Cell Death Differ
, vol.6
, Issue.2
, pp. 175-182
-
-
Hedlund, T.E.1
Meech, S.J.2
Srikanth, S.3
Kraft, A.S.4
Miller, G.J.5
Schaack, J.B.6
-
38
-
-
0031742724
-
Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines
-
Bardon S, Picard K, Martel P. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 1998;32(1): 1-7.
-
(1998)
Nutr Cancer
, vol.32
, Issue.1
, pp. 1-7
-
-
Bardon, S.1
Picard, K.2
Martel, P.3
-
39
-
-
0031841099
-
Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells
-
Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL. Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res 1998;18(2A):823-828.
-
(1998)
Anticancer Res
, vol.18
, Issue.2 A
, pp. 823-828
-
-
Stayrook, K.R.1
McKinzie, J.H.2
Barbhaiya, L.H.3
Crowell, P.L.4
-
40
-
-
0031944598
-
Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors
-
Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998;35(2):95-101.
-
(1998)
Prostate
, vol.35
, Issue.2
, pp. 95-101
-
-
Han, E.K.1
Lim, J.T.2
Arber, N.3
Rubin, M.A.4
Xing, W.Q.5
Weinstein, I.B.6
-
41
-
-
0034713236
-
The human cyclin B1 protein modulates sensitivity of DNA mismatch repair deficient prostate cancer cell lines to alkylating agents
-
Rasmussen LJ, Rasmussen M, Lutzen A, Bisgaard HC, Singh KK. The human cyclin B1 protein modulates sensitivity of DNA mismatch repair deficient prostate cancer cell lines to alkylating agents. Exp Cell Res 2000;257(1):127-134.
-
(2000)
Exp Cell Res
, vol.257
, Issue.1
, pp. 127-134
-
-
Rasmussen, L.J.1
Rasmussen, M.2
Lutzen, A.3
Bisgaard, H.C.4
Singh, K.K.5
-
42
-
-
0034296761
-
Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis
-
Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000;2(4):348-358.
-
(2000)
Mol Ther
, vol.2
, Issue.4
, pp. 348-358
-
-
Hyer, M.L.1
Voelkel-Johnson, C.2
Rubinchik, S.3
Dong, J.4
Norris, J.S.5
-
43
-
-
0031746614
-
Fas ligand is constitutively secreted by prostate cancer cells in vitro
-
Liu QY, Rubin MA, Omene C, Lederman S, Stein CA. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res 1998;4(7):1803-1811.
-
(1998)
Clin Cancer Res
, vol.4
, Issue.7
, pp. 1803-1811
-
-
Liu, Q.Y.1
Rubin, M.A.2
Omene, C.3
Lederman, S.4
Stein, C.A.5
-
44
-
-
0030824454
-
Dominant nature of the resistance to Fas- and tumor necrosis factor-alpha-mediated apoptosis in human prostatic carcinoma cell lines
-
Rokhlin OW, Hostager BS, Bishop GA, Sidorenko SP, Glover RA, Gudkov AV, et al. Dominant nature of the resistance to Fas- and tumor necrosis factor-alpha-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57(18):3941-3943.
-
(1997)
Cancer Res
, vol.57
, Issue.18
, pp. 3941-3943
-
-
Rokhlin, O.W.1
Hostager, B.S.2
Bishop, G.A.3
Sidorenko, S.P.4
Glover, R.A.5
Gudkov, A.V.6
-
45
-
-
0032903236
-
Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis
-
Costa-Pereira AP, Cotter TG. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 1999;80(3-4):371-378.
-
(1999)
Br J Cancer
, vol.80
, Issue.3-4
, pp. 371-378
-
-
Costa-Pereira, A.P.1
Cotter, T.G.2
-
46
-
-
0029739576
-
Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas
-
Takeuchi T, Sasaki Y, Ueki T, Kaziwara T, Moriyama N, Kawabe K, et al. Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas. Int J Cancer 1996;67(5):709-714.
-
(1996)
Int J Cancer
, vol.67
, Issue.5
, pp. 709-714
-
-
Takeuchi, T.1
Sasaki, Y.2
Ueki, T.3
Kaziwara, T.4
Moriyama, N.5
Kawabe, K.6
-
47
-
-
0344019488
-
The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis
-
Muller M, Scaffidi CA, Galle PR, Stremmel W, Krammer PH. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw 1998;9(4):685-686.
-
(1998)
Eur Cytokine Netw
, vol.9
, Issue.4
, pp. 685-686
-
-
Muller, M.1
Scaffidi, C.A.2
Galle, P.R.3
Stremmel, W.4
Krammer, P.H.5
-
48
-
-
0031743648
-
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
-
Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188(11):2033-2045.
-
(1998)
J Exp Med
, vol.188
, Issue.11
, pp. 2033-2045
-
-
Muller, M.1
Wilder, S.2
Bannasch, D.3
Israeli, D.4
Lehlbach, K.5
Li-Weber, M.6
|